Urothelial Bladder Carcinoma | Data + Perspectives: Clinical Investigators Discuss the Optimal Management of Urothelial Bladder Carcinoma

published 2 months ago by Dr Neil Love

Proceedings from a CME symposium held at the 2020 Genitourinary Cancers Symposium. Featuring perspectives from Drs Peter H O’Donnell, Daniel P Petrylak, Elizabeth R Plimack, Jonathan E Rosenberg and Guru Sonpavde. Introduction Program Overview: Dr Neil Love (00:00) Immune Checkpoint Inhibitors for Patients with Nonmetastatic Urothelial Bladder Cancer (UBC) Roundtable Discussion (1:05) Faculty Presentation — Dr Plimack (13:05) Role of Anti-PD-1/PD-L1 Antibodies in the Up-Front Management of Advanced UBC Roundtable Discussion (25:17) Faculty Presentation — Dr Rosenberg (39:50) Application of Anti-PD-1/PD-L1 Antibodies for Progressive Metastatic Disease; Ongoing Investigation of Immune Checkpoint Inhibitors in Advanced UBC Roundtable Discussion (54:11) Faculty Presentation — Dr O’Donnell (1:02:25) Approved and Investigational Antibody-Drug Conjugates for Advanced UBC Roundtable Discussion (1:13:41) Faculty Presentation — Dr Petrylak (1:23:53) FGFR-Targeted Strategies in Advanced UBC Roundtable Discussion (1:35:35) Faculty Presentation — Dr Sonpavde (1:45:18) CME information and select publications

more episodes from Research To Practice | Oncology Videos